摘要
目的 探讨灯盏花素联合神经生长因子对缺血性视神经病变患者的临床效果。方法 选取2014年3月～2016年3月余姚市人民医院眼科接诊的80例缺血性视神经病变患者,随机分为观察组和对照组,每组各40例。对照组采用神经生长因子治疗,臀部注射30 ug,1次/天。观察组在对照组治疗基础上加用灯盏花素治疗,80 mg添加到500 mL葡萄糖中进行静脉滴注,1次/天。比较2组患者视力变化,视野的丢失差异（LV）、视野的平均损害（MD）、视野的平均光敏感度（MS）,不良反应,治疗疗效。结果 治疗后,观察组总有效率显著高于对照组,差异有统计学意义（P〈0.05）;观察组视力显著高于对照组,差异有统计学意义（P〈0.05）;LV、MD显著低于对照组,差异有统计学意义（P〈0.05）,MS显著高于对照组,差异有统计学意义（P〈0.05）;2组不良反应比较差异无统计学意义。结论 灯盏花素联合神经生长因子治疗缺血性视神经病变能够改善患者的视神经功能,提高治疗效果。
Objective To investigate clinical effect of breviscapine combined with nerve growth factor in treatment of ischemic optic neuropathy . Methods 80 patients with ischemic optic neuropathy from March 2014 to March 2016 in our hospital were selected and divided into the control group and observation group, 40 cases in each group.The control group was treated with nerve growth factor, hip injection 30ug, one times a day, while the observation group was treated with breviscapine combined with nerve growth factor, 80 mg breviscapine added to 500 mL glucose intravenous infusion, one times a day.Then the changes of visual acuity, visual field loss difference （LV）, the average damage of vision （MD）, the average vision light sensitivity （ MS ） , adverse reactions, curative effect were compared between two groups.Results After treatment, the total effective rate in the observation group was significantly higher than the control group, the difference was statistically significant （P〈0.05）, the visual acuity of the observation group was significantly higher than that of the control group, the difference was statistically significant （P〈0.05）, LV, MD was significantly lower than the control group, the difference was statistically significant （P〈0.05）, MS was significantly higher than the control group, the difference was statistically significant （P〈0.05）.There was no difference in adverse reactions between the two groups.Conclusion Breviscapine combined with nerve growth factor in the treatment of ischemic optic neuropathy can improve nerve function of patients , improve the therapeutic effect.
出处
《中国生化药物杂志》
CAS
2017年第3期172-174,共3页
Chinese Journal of Biochemical Pharmaceutics
